InVivo Therapeutics to Present and Exhibit at the 65th CNS Annual Meeting

CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company will be giving a poster presentation and exhibiting at the 65th Congress of Neurological Surgeons (CNS) Annual Meeting, to be held in New Orleans, LA, September 26-30, 2015. The e-poster, titled “Novel Surgical Procedure to Implant an Investigational Neuro-Spinal Scaffold Following Myelotomy for Treatment of Acute Traumatic Spinal Cord Injury: A Safety and Feasibility Study,” is co-authored by Lorianne Masuoka, M.D., Kristin Neff, M.S., Thomas Ulich, M.D., and Alex Aimetti, Ph.D. InVivo will also host a networking event at this meeting aimed at engaging and connecting with current and potential Principal Investigators in our clinical study. At this event, Dr. Nicholas Theodore from Barrow Neurological Institute, who performed the first implantation of the Neuro-Spinal Scaffold in a human patient, will be discussing his case experience and narrating his surgical video as a way to inform the neurosurgical community about our novel therapeutic approach.

“Novel Surgical Procedure to Implant an Investigational Neuro-Spinal Scaffold Following Myelotomy for Treatment of Acute Traumatic Spinal Cord Injury: A Safety and Feasibility Study”

“As a leader in the development of therapies for spinal cord injury, it is imperative that we continue to strengthen and expand our network in the neurosurgical community. With a worldwide membership of over 8,000 members, the Congress of Neurological Surgeons is a leader in education and scientific exchange that is dedicated to advancing neurosurgery, and we are pleased to be presenting and exhibiting at their annual meeting,” said Mark Perrin, InVivo’s CEO and Chairman.

A new CEO’s Perspective regarding building value through increased exposure within the scientific and medical community can be found on the InVivo Therapeutics website:

About the Neuro-Spinal Scaffold™

Following an acute spinal cord injury, the biodegradable Neuro-Spinal Scaffold is surgically implanted at the epicenter of the wound and is designed to act as a physical substrate for nerve sprouting. Appositional healing to spare spinal cord tissue, decreased post-traumatic cyst formation, and decreased spinal cord tissue pressure have been demonstrated in preclinical models of spinal cord contusion injury. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and is currently being studied in an Investigational Device Exemption (IDE) pilot study for the treatment of patients with complete (AIS A) traumatic acute spinal cord injury. Neuro-Spinal Scaffold™ is a trademark of InVivo Therapeutics.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit

Related Articles

Back to top button